Will Berkshire Hathaway announce or close a major acquisition (>$10B enterprise value) under Greg Abel's leadership by year-end 2026?

OxyChem's $9.5B close on January 2 is the pivotal new data point. It falls just below the $10B EV threshold and does not resolve YES, but it definitively answers the 'untested capability' concern that anchored the prior 0.23 estimate. Abel demonstrated he can source and close an acquisition within his first 48 hours as CEO. This upgrades deal-sourcing capability from E1 to E2/E3 evidence. The key question now is whether OxyChem was a one-off or signals an active acquisition stance. Abel's zero-buyback FY2025 posture and $369B remaining cash strongly suggest he prefers acquisitions. However, OxyChem is a cyclical oilfield chemicals business — a methodical, value-oriented deal, not a bold transformational one. The 5-criterion discipline framework implies selectivity. Still, with 11 months remaining, the probability of at least one >$10B deal is materially higher than at the 45-day mark. Central estimate: ~37-40%.

The February estimate of 0.23 embedded a significant discount for untested capability. OxyChem resolves this — Abel found, evaluated, and closed a deal in his first days. The more important question is deal frequency. If Abel is in 'acquisition mode' with $369B to deploy, the annual cadence could be 1-2 major deals. Alleghany ($11.6B, 2022) is the reference: Berkshire can and does close >$10B deals when the right target appears. OxyChem at $9.5B being Abel's entry point suggests he is willing to do deals in the $5-20B range — the next one is plausibly above $10B. The 5-criterion framework is discipline, not paralysis. Key risk: OxyChem may have required months of preparation under Buffett's tenure and Abel just executed on a pre-existing pipeline — the next deal might take longer to source independently.

OxyChem is a meaningful update but I weight the sub-threshold nature more cautiously. Abel chose a $9.5B oilfield chemicals deal — not a transformational acquisition. Oilfield chemicals is a cyclical business sensitive to commodity prices, suggesting Abel may see value in industrial businesses at current valuations rather than premium consumer/tech brands Buffett targeted. The 5-criterion discipline framework explicitly sets a high bar. With 11 months remaining and only one deal closed (below threshold), the base rate scenario is: Abel does 0-1 more material deals in 2026, and the probability of that one deal exceeding $10B EV is moderate. I estimate ~36% combining: ~55% chance of another acquisition announcement in 2026, times ~65% chance it exceeds $10B EV.

The OxyChem data point is meaningful but I weight it more conservatively. First, OxyChem at $9.5B is literally below the resolution threshold — Abel's demonstrated deal is a near-miss, not a direct precedent for clearing >$10B. Second, closing a deal that may have been in Buffett's pipeline differs from independently sourcing a new >$10B deal. Third, Abel's 5-criterion discipline framework implies deliberateness: each acquisition must meet a high bar, and finding multiple qualifying targets in a single calendar year is historically uncommon. Berkshire's last two major deals were 2022 (Alleghany, $11.6B) and 2024 (Pilot 100%). That's roughly one major deal per 1-2 years. With one sub-threshold deal already done in 2026, the base rate for an additional >$10B deal in the remaining 10 months is ~30-35%.

I weight the 5-criterion capital discipline framework heavily. Abel explicitly articulated this in his shareholder letter — it is a deliberate, structured approach to capital allocation. This framework implies Abel will pass on many deals that don't meet all five criteria. Combined with Berkshire's structural constraint (only targets >$10B are 'needle-moving' given $780B+ market cap), the universe of qualifying deals is small at any given time. OxyChem's $9.5B close shows willingness to act but at a below-threshold size. The market for large willing sellers at Berkshire-style valuations remains thin. I estimate ~30%: the capability uncertainty is resolved but the opportunity constraint and discipline framework together keep the probability below the prior 0.23 + a large update.

Balancing the bull and bear cases more carefully. Bull: OxyChem removes the single largest uncertainty factor (capability), $369B remains, Abel has shown he wants acquisitions over buybacks, and 11 months is a meaningful window. Bear: OxyChem is below threshold, it may be a pre-existing pipeline item, the discipline framework is explicit, and market valuations remain elevated making willing-seller/buyer price convergence rare. The net update from 0.23 is meaningful but not dramatic — maybe +10-12 percentage points. The capability discount was probably worth ~8-10 points of the prior, and OxyChem resolves most of it while the opportunity-set constraint remains. Central estimate: ~33-35%.

The February 14 estimate of 0.23 was explicitly anchored to Abel being 'entirely untested' — E1 evidence on institutional moat transferability. OxyChem changes this substantially. Abel has now demonstrated deal execution. The $9.5B price is close to threshold — this isn't a tuck-in, it's a substantial acquisition. Zero buybacks throughout FY2025 signals that Abel's capital deployment preference is clearly acquisitions. $369B in dry powder with that preference is a significant setup. The remaining 10+ months of 2026 is meaningful time. I estimate ~37%, reflecting that the capability concern is resolved, the capital preference is confirmed, but the threshold is strict and the market for willing sellers at Berkshire prices is genuinely constrained.

OxyChem provides the critical proof-of-concept but I'm cautious about extrapolating deal frequency. The KHC and OXY equity impairments ($8.26B) signal legacy portfolio stress, which may create competing capital priorities (managing impaired positions, BHE/PacifiCorp utilities). Abel's shareholder letter was operational in tone — setting targets for BNSF operating ratio improvement suggests he is focused on running the businesses he has, not just acquiring new ones. The organic improvement focus and acquisition activity may compete for attention. Still, $369B is enormous and Abel's stated hierarchy (internal opportunities first, then 100% acquisitions) is being followed. I weight ~33%.

This question asked whether Abel would demonstrate deal capability — and he has, with OxyChem. The prior 0.23 embedded a meaningful probability that Abel would spend all of 2026 with zero acquisitions, purely operating mode. That scenario is now significantly less likely. With one deal closed and 11 months remaining, the realistic scenario tree looks like: (A) OxyChem was Abel's one 2026 acquisition, he focuses on integration and operations for the remainder — resolves NO (~55%); (B) Abel sources a second acquisition in 2026, which exceeds $10B threshold — resolves YES (~35%); (C) Abel announces a deal that ultimately falls through or is below threshold — NO (~10%). The YES probability is roughly 35%. The critical unknown remains whether Abel's independent sourcing network is deep enough to find a qualifying target quickly.